Elrexfio (Elranatamab-Bcmm) Patent Expiration, LOE Window & CMS Spending

Elrexfio (Elranatamab-Bcmm) by Pfizer: Biologic BLA (Purple Book Regime), 0 AB generics, $1.2M 2024 CMS Part D & Medicaid spend, and $13,051 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayB761345 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$413K
2024 Medicaid Spend$777K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($13,051 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.